Saracatinib LOXO-292

Saracatinib (AZD0530) is an oral small molecule Src inhibitor developed with the aid of AstraZeneca. AZD0530 is a quinazoline spinoff with aniline substitution at the 4-position, consequently it additionally has EGFR tyrosine kinase inhibitor activity, however the inhibitory undertaking is average. AZD0530 has a robust potential to penetrate the blood-brain barrier. AZD0530 may additionally reverse P-glycoprotein mediated tumor multidrug resistance. AZD0530 has the impact of growing bone density and decreasing ache in the cure of malignant tumor bone metastasis.